Bishop D K, DeBruyne L A, Chan S, Xu S, Eichwald E J
Department of Surgery, University of Michigan, School of Medicine, Ann Arbor 48109, USA.
Transpl Immunol. 1995 Sep;3(3):222-8. doi: 10.1016/0966-3274(95)80028-x.
Mouse hearts transplanted into MHC disparate donors are usually rejected 1 week after placement. It is widely accepted that alloantigen-reactive helper T lymphocytes (HTL) and cytotoxic T lymphocytes (CTL) are the key mediators of acute allograft rejection. This report demonstrates that the presence or absence of 'traditional' graft-reactive HTL and CTL is not necessarily related to allograft survival. In these studies, donor/recipient combinations disparate only at MHC or only at minor histocompatibility (mH) loci were employed. Allograft survival was monitored, donor-reactive IL-2 (interleukin-2) producing HTL and CTL were quantified by modified limiting dilution analysis, and serum levels of cytolytic alloantibody were determined. C57BL/10 hearts (H-2b) transplanted into B10.BR (H-2k) recipients (full MHC disparity) enjoyed prolonged survival despite massive infiltration of the allograft by donor-reactive HTL and CTL. IgM, but not IgG, donor-reactive alloantibody was present in the sera of these mice. Hence, traditional IL-2 producing HTL and CTL were not capable of mediating acute graft rejection, nor of providing help for alloantibody isotype switching in this MHC disparate combination. In contrast, C3H/HeN (H-2k) hearts transplanted into B10.BR (H-2k) recipients (mH disparity only) were acutely rejected. Donor-reactive HTL and CTL were rare or not detectable in these recipients, and cytolytic alloantibody was not detectable. Similar observations were made when B10.BR hearts were transplanted into C3H/HeN recipients. Interestingly, treatment of recipients with anti-CD4 monoclonal antibody prevented rejection of mH disparate allografts. Therefore, CD4+ T cells were required for rejection of mH disparate allografts, but this process was independent of detectable IL-2 production or CTL function. Hence, the significance of monitoring 'traditional' T cell functions should be questioned in certain donor/recipient combinations.
移植到主要组织相容性复合体(MHC)不相合供体体内的小鼠心脏通常在植入后1周被排斥。人们普遍认为,同种抗原反应性辅助性T淋巴细胞(HTL)和细胞毒性T淋巴细胞(CTL)是急性同种异体移植排斥反应的关键介质。本报告表明,“传统的”移植物反应性HTL和CTL的存在与否不一定与同种异体移植存活相关。在这些研究中,采用了仅在MHC或仅在次要组织相容性(mH)位点不相合的供体/受体组合。监测同种异体移植存活情况,通过改良的有限稀释分析法对供体反应性白细胞介素-2(IL-2)产生的HTL和CTL进行定量,并测定细胞溶解性同种抗体的血清水平。将C57BL/10心脏(H-2b)移植到B10.BR(H-2k)受体(完全MHC不相合)体内,尽管供体反应性HTL和CTL大量浸润同种异体移植组织,但移植心脏存活时间延长。这些小鼠血清中存在IgM而非IgG供体反应性同种抗体。因此,传统的产生IL-2的HTL和CTL不能介导急性移植物排斥反应,也不能在这种MHC不相合组合中为同种抗体的同种型转换提供帮助。相比之下,将C3H/HeN(H-2k)心脏移植到B10.BR(H-2k)受体(仅mH不相合)体内会被急性排斥。在这些受体中,供体反应性HTL和CTL很少或无法检测到,细胞溶解性同种抗体也无法检测到。当将B10.BR心脏移植到C3H/HeN受体体内时也有类似观察结果。有趣的是,用抗CD4单克隆抗体治疗受体可防止mH不相合同种异体移植被排斥。因此,CD4 + T细胞是mH不相合同种异体移植排斥所必需的,但这一过程与可检测到的IL-2产生或CTL功能无关。因此,在某些供体/受体组合中,监测“传统的”T细胞功能的意义值得质疑。